Compare OSUR & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSUR | SABS |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 295.7M | 342.1M |
| IPO Year | 2000 | 2020 |
| Metric | OSUR | SABS |
|---|---|---|
| Price | $4.00 | $3.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $3.00 | ★ $10.75 |
| AVG Volume (30 Days) | 397.4K | ★ 480.5K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 78.53 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $167,064,000.00 | N/A |
| Revenue This Year | $4.48 | N/A |
| Revenue Next Year | $7.76 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.08 | $1.85 |
| 52 Week High | $4.58 | $5.15 |
| Indicator | OSUR | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 49.05 | 52.00 |
| Support Level | $3.89 | $3.68 |
| Resistance Level | $4.29 | $4.09 |
| Average True Range (ATR) | 0.18 | 0.17 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 57.27 | 64.52 |
OraSure Technologies Inc is principally engaged in the development, manufacture, marketing, sale and distribution of (i) diagnostics products, and (ii) sample management solutions. It develops products and services that support diagnostic testing and healthcare data analysis, with a focus on improving access to healthcare. The company derives its revenues from the sale of diagnostics products and sample management solutions. Geographically, it generates the maximum revenue from the United States.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.